Aripiprazole- and Lurasidone-Induced Akathisia: A Case Report and Literature Review

Akathisia is a distressing extrapyramidal symptom of antipsychotic medications, characterized by a subjective feeling of inner restlessness and an objective urge to move. While first-generation antipsychotics are often associated with akathisia, second-generation antipsychotics, including partial dopamine agonists, such as aripiprazole and serotonin-dopamine activity modulators like lurasidone, may also cause akathisia. This report details the case of a 46-year-old male with treatment-resistant depression who developed severe akathisia sequentially during augmentation therapy, first with lurasidone and later with aripiprazole. In both instances, the distressing symptoms resolved completely upon discontinuation of the offending agent. This case is significant as it highlights that even low, introductory doses of these commonly used second-generation antipsychotics can precipitate severe akathisia. It underscores the critical need for vigilant clinical monitoring and prompt intervention to prevent patient distress and ensure appropriate management, particularly in complex cases like treatment-resistant depression.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-09-19
DOI
https://doi.org/10.7759/cureus.92704
Citations
3
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
4.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Aripiprazole- and Lurasidone-Induced Akathisia: A Case Report and Literature Review

Kalyan Kandra
3 citations
Cureus
Schizophrenia research and treatment
4.41
article

Aripiprazole- and Lurasidone-Induced Akathisia: A Case Report and Literature Review

Kalyan Kandra
article en
3 citations

Abstract

Akathisia is a distressing extrapyramidal symptom of antipsychotic medications, characterized by a subjective feeling of inner restlessness and an objective urge to move. While first-generation antipsychotics are often associated with akathisia, second-generation antipsychotics, including partial dopamine agonists, such as aripiprazole and serotonin-dopamine activity modulators like lurasidone, may also cause akathisia. This report details the case of a 46-year-old male with treatment-resistant depression who developed severe akathisia sequentially during augmentation therapy, first with lurasidone and later with aripiprazole. In both instances, the distressing symptoms resolved completely upon discontinuation of the offending agent. This case is significant as it highlights that even low, introductory doses of these commonly used second-generation antipsychotics can precipitate severe akathisia. It underscores the critical need for vigilant clinical monitoring and prompt intervention to prevent patient distress and ensure appropriate management, particularly in complex cases like treatment-resistant depression.

CureusVol. 17(9)
Southern Illinois University School of Medicine (US)
Openalex Percentile: Top 5%
Schizophrenia research and treatment
4.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Aripiprazole- and Lurasidone-Induced Akathisia: A Case Report and Literature Review — Kalyan Kandra · Cureus (2025) | TGRS Research Map | TGRS